Tuberculosis diseminada en un paciente con psoriasis severa en tratamiento con adalimumab

La OMS considera la tuberculosis (TBC) una de las principales causas de  muerte y la primera por enfermedades infecciosas. El adalimumab es un  anticuerpo monoclonal que bloquea el efecto del factor de necrosis tumoral  alfa (TNF-a), utilizado mundialmente como tratamiento contra  la psoriasis severa. La TBC latente podria reactivarse como consecuencia  de ese tratamiento. Presentamos el caso de un hombre de 30 anos  con psoriasis en placas severa en tratamiento con adalimumab, que al  cuarto mes evoluciono con TBC diseminada. El agente biologico se suspendio  y el paciente completo el tratamiento antifimico. Luego realizo  tratamiento con secukinumab (anti-IL-17A), con excelente respuesta. Palabras clave: psoriasis, tuberculosis diseminada, adalimumab,  secukinumab. Dermatol. Argent. 2019, 25 (2): 87-89 Disseminated tuberculosis in a patient with severe psoriasis treated with adalimumab Abstract WHO considers tuberculosis (TB) as one of the main causes of death worldwide, the first one among infectious diseases. Adalimumab is a monoclonal antibody that blocks the effect of tumor necrosis factor alpha (TNF-a) and is used widely for the treatment of severe psoriasis. A latent TB may become active as a result of such therapy. We present a case of a 30-year-old man with severe plaque psoriasis treated with adalimumab who evolved with disseminated TB after four. The biologic therapy was withdrawn and and the patient completed the TB treatment. Then, he started therapy with secukinumab (IL-17A) with excellent response. Key words: psoriasis, disseminated tuberculosis, adalimumab, secukinumab. Dermatol. Argent. 2019, 25 (2): 87-89